Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Clinical trial NCT04392154 · COMPLETED

Trial details

NCT number: NCT04392154
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2020-06-15
Primary completion: 2024-07-19
Enrollment: 1153

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.